Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Salarius Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SLRX
Nasdaq
2834
www.salariuspharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
- Feb 3rd, 2025 1:00 pm
Sector Update: Health Care Stocks Rise Late Afternoon
- Jan 13th, 2025 9:08 pm
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement
- Jan 13th, 2025 1:00 pm
Salarius: Q3 Earnings Snapshot
- Nov 15th, 2024 12:25 am
Salarius: Q2 Earnings Snapshot
- Aug 9th, 2024 9:21 pm
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
- Jun 17th, 2024 12:00 pm
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
- Jun 12th, 2024 12:00 pm
SLRX Pursues Important Goal
- Apr 2nd, 2024 12:23 pm
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 22nd, 2024 8:05 pm
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
- Feb 22nd, 2024 1:00 pm
Scroll